Long Term Portfolio
Long-Term Portfolio
| Ticker | First Mention | My Entry | Last | P/L % | Market Cap |
|---|---|---|---|---|---|
| ALGS | — | — | — | — | —— |
| SPRO | — | — | — | — | —— |
EOD and Market cap from publicly available data.
Updates:
SPRO: Waiting for FDA approval
ALGS: Patiently waiting for Phase 2 Data
Watchlist
| Ticker | First Mention | Entry | Exit | Latest Price | P/L % |
|---|---|---|---|---|---|
| LTRN | — | — | — | — | — |
| IVA | — | — | — | — | — |
| SLDB | — | — | — | — | — |
| CGTX | — | — | — | — | — |
EOD prices from publicly available data. P/L calculated from Entry to Exit price.
Remarks
LTRN: Took profit at $4.50 and waiting for re-entry since the expected results weren't published in September, and an offering might be imminent.
IVA: Took profit at $7.85 and waiting for re-entry as the price gap between the French Exchange and NASDAQ were unsustainable. Detailed information here
SLDB: Took 60% gain, some short term spike from Prasad's departure news. Will consider reentry later shortly.
CGTX : I closed my remaining position at 81% profit after listening to the earning call on March 26th, 2026. My initial bullish stance was based on the progress of AD phase 3 trials. However, considering the management’s current direction, the initiation of AD phase 3 seems unlikely unless they anticipate the topline data from START. The focus appears to have shifted to DLB, but it will take at least another year or two to determine the company’s future trajectory. Consequently, multiple dilutions are inevitable in the coming years.
Disclaimer
The information provided on this website is for informational purposes only and should not be construed as
financial, investment, legal, or professional advice. While efforts are made to ensure accuracy, no guarantee
is given regarding completeness or reliability. Visitors should conduct their own research or consult a qualified
advisor before making any decisions. External links are provided for convenience and do not imply endorsement.